Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Evaluating the Relationship between Cathepsins and Papillary Thyroid Carcinoma: A Mendelian Randomization Study
file format pdf download PDF

Abstract

Background

Papillary Thyroid Carcinoma (PTC) is the most common thyroid cancer, with an etiology and progression that are not fully understood. Research suggests a link between cathepsins and PTC, but the causal nature of this link is unclear. This study uses Mendelian Randomization (MR) to investigate if cathepsins causally influence PTC risk.

Methods

We applied univariable and multivariable MR analyses using genetic variants as proxies for cathepsin levels. Genetic data for cathepsins were sourced from the INTERVAL study, while PTC data came from the Finnish Genome-Wide Association Study database. Our analysis employed several MR methods, including the Inverse Variance Weighted (IVW) approach, MR-Egger, and the Weighted Median method, to provide comprehensive insights and address possible pleiotropy.

Results

MR findings suggest a significant causal association between higher cathepsin levels and increased PTC risk. Notably, genetic variants indicating higher cathepsin Z expression were positively causal associated with PTC risk (OR:1.1190, 95% CI: 1.0029-1.2486), multivariable analysis confirmed significant carcinogenesis role of cathepsin Z in PTC (OR: 1.1593, 95% CI: 1.0137-1.3258), with results consistent across various tests, indicating a robust relationship.

Conclusion

This study established a causal link between cathepsin levels and PTC risk, emphasizing the roles of cathepsin Z in its progression. These insights could lead to new therapeutic strategies targeting these enzymes. Further research is necessary to understand the underlying biological mechanisms and their clinical implications.

© 2025 The Author(s). Published by Bentham Science Publishers
© 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303305715240912172648
2025-01-08
2025-05-24

  • From This Site

    /content/journals/emiddt/10.2174/0118715303305715240912172648
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. Chen D.W. Lang B.H.H. McLeod D.S.A. Newbold K. Haymart M.R. Thyroid cancer. Lancet 2023 401 10387 1531 1544 10.1016/S0140‑6736(23)00020‑X 37023783
    [Google Scholar]
  2. Wang Y. Mei J. Zhang Y. He X. Zheng X. Tan J. Jia Q. Li N. Li D. Wang Y. Meng Z. Cathepsin F genetic mutation is associated with familial papillary thyroid cancer. Am. J. Med. Sci. 2022 364 4 414 424 10.1016/j.amjms.2022.03.017 35447134
    [Google Scholar]
  3. Tedelind S. Poliakova K. Valeta A. Hunegnaw R. Yemanaberhan E.L. Heldin N.E. Kurebayashi J. Weber E. Kopitar-Jerala N. Turk B. Bogyo M. Brix K. Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol. Chem. 2010 391 8 923 935 10.1515/bc.2010.109 20536394
    [Google Scholar]
  4. Tan J. Qian X. Song B. An X. Cai T. Zuo Z. Ding D. Lu Y. Li H. Integrated bioinformatics analysis reveals that the expression of cathepsin S is associated with lymph node metastasis and poor prognosis in papillary thyroid cancer. Oncol. Rep. 2018 40 1 111 122 10.3892/or.2018.6428 29749483
    [Google Scholar]
  5. Kim E.K. Song M.J. Jang H.H. Chung Y.S. Clinicopathologic analysis of cathepsin b as a prognostic marker of thyroid cancer. Int. J. Mol. Sci. 2020 21 24 9537 10.3390/ijms21249537 33333840
    [Google Scholar]
  6. Khaket T.P. Kwon T.K. Kang S.C. Cathepsins: Potent regulators in carcinogenesis. Pharmacol. Ther. 2019 198 1 19 10.1016/j.pharmthera.2019.02.003 30763594
    [Google Scholar]
  7. Linders D.G.J. Bijlstra O.D. Fallert L.C. Hilling D.E. Walker E. Straight B. March T.L. Valentijn A.R.P.M. Pool M. Burggraaf J. Basilion J.P. Vahrmeijer A.L. Kuppen P.J.K. Cysteine cathepsins in breast cancer: Promising targets for fluorescence-guided surgery. Mol. Imaging Biol. 2023 25 1 58 73 10.1007/s11307‑022‑01768‑4 36002710
    [Google Scholar]
  8. Chen S. Dong H. Yang S. Guo H. Cathepsins in digestive cancers. Oncotarget 2017 8 25 41690 41700 10.18632/oncotarget.16677 28402938
    [Google Scholar]
  9. Bhattacharyya C. Chakraborty S. Sengupta R. NO news: S-(de)nitrosylation of cathepsins and their relationship with cancer. Anal. Biochem. 2022 655 114872 10.1016/j.ab.2022.114872 36027970
    [Google Scholar]
  10. Mustafa A Elkhamisy F Arghiani N Potential crosstalk between pericytes and cathepsins in the tumour microenvironment. Biomed. Pharmacother. 2023 164 114932 10.1016/j.biopha.2023.114932
    [Google Scholar]
  11. Mulita F Iliopoulos F Tsilivigkos C Cancer rate of Bethesda category II thyroid nodules Med. Glas. (Zenica) 2022 169 1 21 10.17392/1413‑21
    [Google Scholar]
  12. Mulita F. Plachouri M.K. Liolis E. Vailas M. Panagopoulos K. Maroulis I. Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS). Endokrynol. Pol. 2021 72 2 143 144 10.5603/EP.a2021.0018 33749812
    [Google Scholar]
  13. Emdin C.A. Khera A.V. Kathiresan S. Mendelian randomization. JAMA 2017 318 19 1925 1926 10.1001/jama.2017.17219 29164242
    [Google Scholar]
  14. Davey Smith G. Hemani G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 2014 23 R1 R89 R98 10.1093/hmg/ddu328 25064373
    [Google Scholar]
  15. Birney E. Mendelian randomization. Cold Spring Harb. Perspect. Med. 2021 12 4 a041302 10.1101/cshperspect.a041302 34872952
    [Google Scholar]
  16. Bowden J. Holmes M.V. Meta-analysis and mendelian randomization: A review. Res. Synth. Methods 2019 10 4 486 496 10.1002/jrsm.1346 30861319
    [Google Scholar]
  17. Sanderson E. Multivariable mendelian randomization and mediation. Cold Spring Harb. Perspect. Med. 2021 11 2 a038984 10.1101/cshperspect.a038984 32341063
    [Google Scholar]
  18. Sun B.B. Maranville J.C. Peters J.E. Stacey D. Staley J.R. Blackshaw J. Burgess S. Jiang T. Paige E. Surendran P. Oliver-Williams C. Kamat M.A. Prins B.P. Wilcox S.K. Zimmerman E.S. Chi A. Bansal N. Spain S.L. Wood A.M. Morrell N.W. Bradley J.R. Janjic N. Roberts D.J. Ouwehand W.H. Todd J.A. Soranzo N. Suhre K. Paul D.S. Fox C.S. Plenge R.M. Danesh J. Runz H. Butterworth A.S. Genomic atlas of the human plasma proteome. Nature 2018 558 7708 73 79 10.1038/s41586‑018‑0175‑2 29875488
    [Google Scholar]
  19. Kurki M.I. Karjalainen J. Palta P. Sipilä T.P. Kristiansson K. Donner K.M. Reeve M.P. Laivuori H. Aavikko M. Kaunisto M.A. Loukola A. Lahtela E. Mattsson H. Laiho P. Della Briotta Parolo P. Lehisto A.A. Kanai M. Mars N. Rämö J. Kiiskinen T. Heyne H.O. Veerapen K. Rüeger S. Lemmelä S. Zhou W. Ruotsalainen S. Pärn K. Hiekkalinna T. Koskelainen S. Paajanen T. Llorens V. Gracia-Tabuenca J. Siirtola H. Reis K. Elnahas A.G. Sun B. Foley C.N. Aalto-Setälä K. Alasoo K. Arvas M. Auro K. Biswas S. Bizaki-Vallaskangas A. Carpen O. Chen C.Y. Dada O.A. Ding Z. Ehm M.G. Eklund K. Färkkilä M. Finucane H. Ganna A. Ghazal A. Graham R.R. Green E.M. Hakanen A. Hautalahti M. Hedman Å.K. Hiltunen M. Hinttala R. Hovatta I. Hu X. Huertas-Vazquez A. Huilaja L. Hunkapiller J. Jacob H. Jensen J.N. Joensuu H. John S. Julkunen V. Jung M. Junttila J. Kaarniranta K. Kähönen M. Kajanne R. Kallio L. Kälviäinen R. Kaprio J. Kerimov N. Kettunen J. Kilpeläinen E. Kilpi T. Klinger K. Kosma V.M. Kuopio T. Kurra V. Laisk T. Laukkanen J. Lawless N. Liu A. Longerich S. Mägi R. Mäkelä J. Mäkitie A. Malarstig A. Mannermaa A. Maranville J. Matakidou A. Meretoja T. Mozaffari S.V. Niemi M.E.K. Niemi M. Niiranen T. O´Donnell C.J. Obeidat M. Okafo G. Ollila H.M. Palomäki A. Palotie T. Partanen J. Paul D.S. Pelkonen M. Pendergrass R.K. Petrovski S. Pitkäranta A. Platt A. Pulford D. Punkka E. Pussinen P. Raghavan N. Rahimov F. Rajpal D. Renaud N.A. Riley-Gillis B. Rodosthenous R. Saarentaus E. Salminen A. Salminen E. Salomaa V. Schleutker J. Serpi R. Shen H. Siegel R. Silander K. Siltanen S. Soini S. Soininen H. Sul J.H. Tachmazidou I. Tasanen K. Tienari P. Toppila-Salmi S. Tukiainen T. Tuomi T. Turunen J.A. Ulirsch J.C. Vaura F. Virolainen P. Waring J. Waterworth D. Yang R. Nelis M. Reigo A. Metspalu A. Milani L. Esko T. Fox C. Havulinna A.S. Perola M. Ripatti S. Jalanko A. Laitinen T. Mäkelä T.P. Plenge R. McCarthy M. Runz H. Daly M.J. Palotie A. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 2023 613 7944 508 518 10.1038/s41586‑022‑05473‑8 36653562
    [Google Scholar]
  20. Zhang X. Ze Y. Sang J. Shi X. Bi Y. Shen S. Zhang X. Zhu D. Risk factors and diagnostic prediction models for papillary thyroid carcinoma. Front. Endocrinol. (Lausanne) 2022 13 938008 10.3389/fendo.2022.938008 36133306
    [Google Scholar]
  21. Mao J. Zhang Q. Zhang H. Zheng K. Wang R. Wang G. Risk factors for lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis. Front. Endocrinol. (Lausanne) 2020 11 265 10.3389/fendo.2020.00265 32477264
    [Google Scholar]
  22. Nieto H.R. Thornton C.E.M. Brookes K. Nobre de Menezes A. Fletcher A. Alshahrani M. Kocbiyik M. Sharma N. Boelaert K. Cazier J.B. Mehanna H. Smith V.E. Read M.L. McCabe C.J. Recurrence of papillary thyroid cancer: A systematic appraisal of risk factors. J. Clin. Endocrinol. Metab. 2022 107 5 1392 1406 10.1210/clinem/dgab836 34791326
    [Google Scholar]
  23. Frolova A.S. Tikhomirova N.K. Kireev I.I. Zernii E.Y. Parodi A. Ivanov K.I. Zamyatnin A.A. Jr Expression, intracellular localization, and maturation of cysteine cathepsins in renal embryonic and cancer cell lines. Biochemistry (Mosc.) 2023 88 7 1034 1044 10.1134/S0006297923070143 37751872
    [Google Scholar]
  24. Wei S. Liu W. Xu M. Qin H. Liu C. Zhang R. Zhou S. Li E. Liu Z. Wang Q. Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer. Br. J. Cancer 2022 126 12 1795 1805 10.1038/s41416‑022‑01744‑3 35217799
    [Google Scholar]
  25. Zhang F. Liang J. Lu Y. Tang Y. Liu S. Wu K. Zhang F. Lu Y. Liu Z. Wang X. Macrophage-specific cathepsin as a marker correlated with prognosis and tumor microenvironmental characteristics of clear cell renal cell carcinoma. J. Inflamm. Res. 2022 15 6275 6292 10.2147/JIR.S375250 36386587
    [Google Scholar]
  26. Al-Hashimi A. Venugopalan V. Sereesongsaeng N. Tedelind S. Pinzaru A.M. Hein Z. Springer S. Weber E. Führer D. Scott C.J. Burden R.E. Brix K. Significance of nuclear cathepsin V in normal thyroid epithelial and carcinoma cells. Biochim. Biophys. Acta Mol. Cell Res. 2020 1867 12 118846 10.1016/j.bbamcr.2020.118846 32910988
    [Google Scholar]
  27. Wang J. Chen L. Li Y. Guan X.Y. Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. PLoS One 2011 6 9 e24967 10.1371/journal.pone.0024967 21966391
    [Google Scholar]
  28. Akkari L. Gocheva V. Kester J.C. Hunter K.E. Quick M.L. Sevenich L. Wang H.W. Peters C. Tang L.H. Klimstra D.S. Reinheckel T. Joyce J.A. Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev. 2014 28 19 2134 2150 10.1101/gad.249599.114 25274726
    [Google Scholar]
  29. Batista A.A.S. Franco B.M. Perez M.M. Pereira E.G. Rodrigues T. Wroclawski M.L. Fonseca F.L.A. Suarez E.R. Decreased levels of cathepsin Z mRNA expressed by immune blood cells: Diagnostic and prognostic implications in prostate cancer. Braz. J. Med. Biol. Res. 2021 54 10 e11439 10.1590/1414‑431x2021e11439 34378678
    [Google Scholar]
  30. Fang Y. Zhang D. Hu T. Zhao H. Zhao X. Lou Z. He Y. Qin W. Xia J. Zhang X. Ye L. KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation. Cancer Med. 2019 8 7 3544 3552 10.1002/cam4.2226 31090199
    [Google Scholar]
  31. Lines K.E. Chelala C. Dmitrovic B. Wijesuriya N. Kocher H.M. Marshall J.F. Crnogorac-Jurcevic T. S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells. Am. J. Pathol. 2012 180 4 1485 1494 10.1016/j.ajpath.2011.12.031 22330678
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303305715240912172648
Loading
Evaluating the Relationship between Cathepsins and Papillary Thyroid Carcinoma: A Mendelian Randomization Study
Bentham Science Publishers ; https://doi.org/10.2174/0118715303305715240912172648
/content/journals/emiddt/10.2174/0118715303305715240912172648
/content/journals/emiddt/10.2174/0118715303305715240912172648
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: mendelian randomization ; lysosomal proteases ; cathepsins ; causal relationships ; fine-needle aspiration ; Papillary thyroid carcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test